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OBJECTIVES: Osteonecrosis of the jaw (ONJ) is a
potentially severe adverse effect of bisphosphonates
(BP). Although the risk of ONJ increases with increasing
duration of BP treatment, there are currently no reli-
able estimates of the ONJ time to onset (TTO). The
objective of this study was to estimate the TTO and
associated risk factors in BP-treated patients.
SUBJECTS AND METHODS: Retrospective analysis of
data from 22 secondary care centres in seven countries
relevant to 349 patients who developed BP-related ONJ
between 2004 and 2012.
RESULTS: The median (95%CI) TTO was 6.0 years in
patients treated with alendronate (n = 88) and 2.2 years
in those treated with zoledronate (n = 218). Multivari-
able Cox regression showed that dentoalveolar surgery
was inversely associated, and the use of antiangiogenics
directly associated, with the TTO in patients with can-
cer treated with zoledronate.
CONCLUSIONS: The incidence of ONJ increases with
the duration of BP therapy, with notable differences
observed with respect to BP type and potency, route of
administration and underlying disease. When data are
stratified by BP type, a time of 6.0 and 2.2 years of oral
alendronate and intravenous zoledronate therapy,
respectively, is required for 50% of patients to develop
ONJ. After stratification by disease, a time of 5.3 and
2.2 years of BP therapy is required for 50% of patients
with osteoporosis and cancer, respectively, to develop
ONJ. These findings have significant implications for the
design of future clinical studies and the development of
risk-reduction strategies aimed at either assessing or
modulating the risk of ONJ associated with BP.
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Introduction
Osteonecrosis of the jaw (ONJ) is a serious adverse effect
of therapy with bisphosphonates (BP) and other anti-
resorptive agents (Ruggiero et al, 2009; Sivolella et al,
2013). Affected individuals often present with areas of
necrotic ischemic jawbone exposed through fenestration of
the oral mucosa or facial skin (Filleul et al, 2010), while
approximately one in four patients present with necrotic
jawbone covered by intact mucosa (non-exposed variant)
(Fedele et al, 2010). Other manifestations include pain,
secondary infection, tooth loss, ﬁstula formation, patho-
logical fractures, sinusitis and oroantral communication
(Filleul et al, 2010). It has been estimated that ONJ devel-
ops in up to 7% of patients with cancer using intravenous
BP and in approximately 0.12% of osteoporosis patients
taking oral BP (K€uhl et al, 2012).
The pathogenic mechanisms of, and the risk factors for,
ONJ are still controversial (Landesberg et al, 2011). For
instance, several studies have reported that the risk of
ONJ is greater in patients who have undergone surgical
procedures to the jaw bones (e.g. dental extraction)
(Campisi et al, 2014). However, it is also known that
many ONJ cases, possibly up to 30–40%, are not trig-
gered by surgical interventions (Filleul et al, 2010). Less
controversial is the association between the incidence of
ONJ and the cumulative dose and duration of BP treat-
ment (Thumbigere-Math et al, 2012; Fleisher et al, 2013),
in keeping with type C adverse drug reactions (Edwards
and Aronson, 2000). Indeed, the incidence of ONJ is low
during the ﬁrst few years of BP treatment and increases sub-
stantially thereafter (Barasch et al, 2011). However, it is
important to note that there is a great variability and incon-
sistency in the time to ONJ (TTO) reported in the literature,
possibly because of different study designs and diagnostic
criteria, and generally low sample sizes (Bamias et al,
2005; Mavrokokki et al, 2007; Pozzi et al, 2007; Boonya-
pakorn et al, 2008; Vahtsevanos et al, 2009; Saia et al,
2010; Hasegawa et al, 2012; Watters et al, 2013).
A precise estimate of TTO is important for the design of
clinical trials. Trials where follow-up is too short would in
fact miss most incident cases and provide ﬂawed estimates
of ONJ incidence and its risk factors. A precise estimate of
TTO is also important for developing risk-reduction strate-
gies (e.g. BP dosage reduction or cessation) and surveil-
lance programmes (Fedele et al, 2009). To obtain a more
precise estimate of TTO, we have studied the clinical data
collected in GENVABO, a multicentre cross-sectional study
aimed at identifying genetic variants predisposing to BP-
related ONJ.
Methods
Study design
We performed a retrospective secondary analysis of data belonging to a
cohort of patients with ONJ enrolled into the GENVABO (GENetic
VAriants as Biomarkers of jaw Osteonecrosis associated with
bisphosphonates) study, a genomewide association study with the primary
aim of identifying genetic variants that predispose to ONJ. The present
report follows the STROBE recommendations (von Elm et al, 2008).
Setting and inclusion criteria
GENVABO study was designed by investigators at the University Col-
lege London and included a total of twenty-two international clinical cen-
tres with an interest in the diagnosis and management of ONJ. The ethics
committees of the coordinating centre (Central London REC 4, reference
08/H0715/69) and participating sites approved the study, and all patients
gave their written informed consent to participate. Patients referred to the
participating centres between January 2004 and June 2012 were eligible
for GENVABO if they had (i) ONJ diagnosed as per AAOMS criteria
(Ruggiero et al, 2009) (Ruggiero et al, 2014) and (ii) non-exposed ONJ
deﬁned as reported by Fedele et al and other authors (Junquera and Gal-
lego, 2008; Fedele et al, 2010; Patel et al, 2011). ONJ was diagnosed
and adjudicated in all cases by local multidisciplinary teams of specialists
in oral medicine, oral and maxillofacial surgery, oncology, haematology,
rheumatology and radiology.
Data collection
Clinical charts of consecutive patients with ONJ recruited into the GEN-
VABO study between January 2004 and June 2012 were reviewed, and
the data of interest were collected between October 2008 and June 2012.
Such data were extracted by local investigators and entered into a stan-
dardized case report form. All data were inputted into a deﬁnitive data-
base using a double-entry process performed by two different
investigators. The data extracted for the present analysis included the fol-
lowing: (i) age, gender and race; (ii) details of BP therapy including BP
type, date of start and length of therapy, and indication for BP use; (iii)
details of ONJ including date of diagnosis, site and type; (iv) dental his-
tory including history of dentoalveolar surgery and use of dentures pre-
ceding ONJ diagnosis; (v) medical history including type 2 diabetes
mellitus (T2DM) and use of corticosteroids and antiangiogenics; (vi)
smoking history; and (vii) recruiting centre and relevant country. For
patients who had been treated with more than one type of BP, the BP
used for the longest time was used for the present analysis. The data set
was reviewed by a central study panel and underwent data cleaning and
veriﬁcation according to standard procedures. Stata 14.1 (Stata Corp.,
College Station, TX, USA) programs were written to ensure the repro-
ducibility of data management and data cleaning.
Study objectives
The main aim of GENVABO is to identify genetic variants associated with
the risk of developing ONJ. The primary objective of the present secondary
analysis was to estimate TTO in patients with BP-related ONJ. TTO was
deﬁned as the number of years elapsed between the initiation of BP therapy
and the diagnosis of ONJ as outlined above. We did not attempt to differen-
tiate the time to diagnosis from the time to development/onset, as the early
symptoms of ONJ can be non-speciﬁc and they are difﬁcult to assess retro-
spectively. We also calculated the cumulative incidence of ONJ and evalu-
ated the association of TTO with potential risk factors (Hasegawa et al,
2012; Thumbigere-Math et al, 2012; Fleisher et al, 2013).
Statistical analysis
The point estimates and the 95% conﬁdence interval of TTO were calcu-
lated using the Kaplan–Meier estimator (Hosmer et al, 2011). Kaplan–
Meier curves for TTO were stratiﬁed by disease (metastatic breast cancer
vs multiple myeloma vs metastatic prostate cancer vs other cancers vs
osteoporosis), cancer (yes vs no) and BP (alendronate vs ibandronate vs
pamidronate vs zoledronate). Multivariable Cox regression was used to
test whether TTO was associated with gender (discrete, male vs female),
age (continuous, decade), dentoalveolar surgery (discrete, yes vs no),
T2DM (discrete, yes vs no), use of steroids (discrete, yes vs no) and use
of antiangiogenics (discrete, yes vs no) in patients with cancer (Model 1)
and in non-cancer patients (Model 2) (Hosmer et al, 2011). Cluster conﬁ-
dence intervals were calculated using the study country as cluster. The
proportional hazard assumption made by Cox regression was checked
using Schoenfeld residuals (Hosmer et al, 2011). Multivariable fractional
polynomials were used to test whether the multivariable relationship of
TTO with age was linear (Royston and Sauerbrei, 2008). Statistical anal-
ysis was performed using Stata version 14.1.
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Results
Details of the cohort
Clinical notes of 384 consecutive patients with BP-
related ONJ recruited into GENVABO study were
available for analysis. Missing or conﬂicting data were
identiﬁed for 35 (9%) patients, who were excluded from
further analysis. The majority of the 349 analysed
patients (Table 1) were of Caucasian origin (93%); 85%
were aged ≥ 60 years; and 71% were females. The
majority (n = 318; 91%) of the participants had exposed
ONJ. The most common indications for ONJ treatment
were osteoporosis (OP, 32%), multiple myeloma (MM,
27%), metastatic breast cancer (MBC, 24%) and meta-
static prostate cancer (MPC, 10%). Zoledronate (ZOL,
63%) and alendronate (ALE, 25%) were the two most
commonly employed BP, followed by pamidronate
(PAM, 5%), ibandronate (IBA, 4%) and risedronate
(RIS, 3%). Concomitant corticosteroids and antiangiogen-
ics (bevacizumab, sunitinib, thalidomide, lenalidomide,
bortezomib) were used in 22% and 14% of patients,
respectively. Dentoalveolar surgery preceding ONJ devel-
opment was reported by 53% of patients, tobacco smok-
ing by 21% and T2DM by 10%.
Time to ONJ onset
In the whole cohort (n = 349), the 50th (95%CI) per-
centile of TTO was 3.2 (2.8–3.7) years, the 25th percentile
1.7 (1.4–1.9) years and the 75th percentile 5.8 (5.2–6.2)
years. The minimum and maximum TTO were 0.1 and
19.9 years, respectively.
Table 1 shows the median TTO after stratiﬁcation on
several variables including disease and BP type. In brief,
when stratiﬁed by BP type, the median (50th percentile)
TTO was 6.0 (5.3–6.4) years for ALE and 2.2 (2.1–2.6)
for ZOL. When stratiﬁed by disease, the median TTO was
5.3 (4.4–6.1) years for OP, 3.1 (2.2–3.6) for MBC and 2.3
(2.1–3.0) for MM. The median TTO was 2.2 (2.1–2.8)
years for all patients with cancer (n = 237).
Figure 1a–c presents the Kaplan–Meier plots of the
cumulative incidence of ONJ in patients stratiﬁed by dis-
ease, cancer and BP type. Figure 1a shows that ONJ
developed faster in patients with cancer than in those
with osteoporosis. Among patients with different cancer
types, development was most rapid in those with MPC,
followed by OC, MM and MBC (Figure 1c). Figure 1b
shows that ONJ developed faster in patients treated with
ZOL, RIS and IBA than in those treated with PAM and
ALE.
Table 2 shows the multivariable Cox regression models
used to evaluate the association between TTO and poten-
tial predictors in cancer and non-cancer patients. Model 1
refers to patients with cancer taking ZOL (212 of 237
patients with cancer, 89%), while Model 2 refers to non-
cancer patients taking ALE (84 of 112 patients, 75%). A
history of dentoalveolar surgery was inversely associated
(hazard ratio, HR = 0.71, 95% CI: 0.56–0.91) and the use
of antiangiogenics (HR = 1.10, 95% CI: 1.01–1.19)
directly associated with TTO in the subgroup of patients
with cancer taking ZOL (Model 1).
Discussion
Cumulative dosage and duration of anti-resorptive therapy
are two of the most consistently reported risk factors for
ONJ development (Thumbigere-Math et al, 2012; Fleisher
et al, 2013), and there remains little doubt that ONJ is a
time- and dose-related adverse effect. However, data
regarding TTO are controversial as they vary signiﬁcantly
among studies (Palaska et al, 2009). Fleisher et al (Fle-
isher et al, 2013) reported a median time of 3 and 5 years
for ONJ to develop in individuals using intravenous and
oral BP, respectively, whereas a 2009 review reported a
mean time of 1.8 and 4.6 years after ZOL and ALE ther-
apy, respectively (Palaska et al, 2009). Other authors
reported that ONJ developed after only 4 months of ZOL
therapy, which they suggest was possibly triggered by
invasive dental surgical procedures (Saussez et al, 2009).
Moreover, a recent study of 191 ONJ cases recruited in a
primary care setting (dental practice-based research
network) reported a 10-fold increase in risk of ONJ asso-
ciated with <2 years of BP therapy, which increased to
Table 1 Details of the study cohort and time to event stratiﬁed by poten-
tial risk factors
Potential risk factor N %
Median Time
to event (years)
(95%CI)
Age
(decade)
30–39 2 0.6 2.2 (2.2–NA)
40–49 8 2.3 3.7 (0.4–7.5)
50–59 41 11.7 2.4 (1.6–3.5)
60–69 125 35.8 3.3 (2.8–4.3)
70–79 134 38.4 2.8 (2.2–3.7)
80–89 39 11.2 4.2 (2.9–5.8)
Total 349 100 3.2 (2.8–3.7)
Gender Female 247 70.8 3.9 (3.2–4.3)
Male 102 29.2 2.1 (1.8–2.6)
Race Caucasian 323 92.6 3.2 (2.8–3.7)
Other 26 7.4 2.9 (2.4–5.4)
Underlying
disease
Metastatic
Breast Cancer (MBC)
84 24.1 3.1 (2.2–3.6)
Multiple Myeloma (MM) 93 26.6 2.3 (2.1–3.0)
Metastatic Prostate
Cancer (MPC)
33 9.5 1.8 (1.6–2.1)
Other Cancers (OC) 27 7.7 2.1 (1.0–2.8)
Osteoporosis (OP) 112 32.1 5.3 (4.4–6.1)
BP type Alendronate (ALE) 88 25.2 6.0 (5.3–6.4)
Ibandronate (IBA) 15 4.3 2.1 (0.6–3.2)
Pamidronate (PAM) 17 4.9 6.2 (4.6–7.2)
Risedronate (RIS) 11 3.2 2.4 (0.3–4.7)
Zoledronate (ZOL) 218 62.5 2.2 (2.1–2.6)
Medical
History
Corticosteroids 76 21.8 3.2 (2.6–4.1)
Antiangiogenicsa 49 14 2.3 (1.8–3.2)
Type 2 diabetes
mellitus
34 9.7 2.9 (2.3–4.6)
Smoking 74 21.1 3.4 (2.6–4.5)
Dental
History
Dentoalveolar surgery 186 53.3 3.9 (3.2–4.5)
Denture use 73 20.9 4.2 (2.7–5.3)
ONJ
features
Non-exposed type 31 8.9 3.3 (1.7–5.8)
Exposed type 318 91.1 3.2 (2.8–3.7)
Maxilla 88 25.2 3.3 (2.7–3.9)
Mandible 227 65 2.9 (2.4–3.6)
Both maxilla
and mandible
34 9.7 4.2 (3.0–5.1)
N, number of patients; NA, not available.
aBevacizumab, sunitinib, thalidomide, lenalidomide, bortezomib.
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40-fold among individuals treated with BP for more than
2 years (Barasch et al, 2011).
Such inconsistency in the data on TTO has negative
clinical consequences as it can hinder the delivery of
potential risk-reduction strategies such as prophylactic
dental measures and BP dosage reduction or discontinua-
tion. It can also affect the delivery of clinical surveillance
programmes (Kyle et al, 2007; Kyrgidis et al, 2013) and
cause confusion in the interpretation of clinical studies.
For example, clinical trials with a short observation time,
for example shorter than the median TTO, would miss a
signiﬁcant number of incident cases and therefore provide
ﬂawed estimates of ONJ incidence and its risk factors.
The most likely reasons accounting for the inconsistency
and variability of current TTO estimates are different
study designs, generally low sample sizes, ambiguous def-
initions of TTO, short follow-up times and diagnostic cri-
teria limited to exposed ONJ (Palaska et al, 2009). The
present study was undertaken with the aim of overcoming
these limitations. A signiﬁcant strength of our study is the
large sample size (n = 349), making it the largest study
performed so far to investigate TTO. Another strength of
our study is the use of a strict deﬁnition of TTO as the
time elapsed between the commencement of BP therapy
and ONJ diagnosis, as determined by a multidisciplinary
team. Previous studies have interchangeably used TTO as
per clinicians’ diagnosis and TTO as based on symptoms
reported by patients (Bamias et al, 2005; Mavrokokki
et al, 2007; Pozzi et al, 2007; Boonyapakorn et al, 2008;
Vahtsevanos et al, 2009; Saia et al, 2010; Hasegawa et al,
2012; Watters et al, 2013), and other studies have used
unclear diagnostic criteria (Palaska et al, 2009). On the
contrary, our study deﬁned TTO precisely and consistently
among centres and avoided the bias associated with the
mixing of the diagnoses made by physicians and those
made by patients (Lazarovici et al, 2009). The use of
strict diagnostic criteria in multicentre cross-sectional
cohort studies reduces the risk of selection bias (Hudson
et al, 2005).
We estimated a median TTO of 3.2 years in the whole
cohort. When stratiﬁed by BP type, the median TTO was
6.0 years for ALE and 2.2 for ZOL. The corresponding
ﬁgures were 2.1 years for IBA, 2.4 years for RIS and
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Figure 1 Kaplan-Meier curves of number and percentage of patients
developing ONJ over time. The data are obtained from a retrospective
cohort study including only patients who developed ONJ (see text for
details). Stratiﬁcation by (a) underlying disease (cancer vs non-cancer),
(b) bisphosphonate type, and (c) underlying disease (all). MBC, meta-
static breast cancer; MPC, metastatic prostate cancer; MM, multiple mye-
loma; OC, other cancers; OP, osteoporosis; ALE, alendronate; PAM,
pamidronate, ZOL, zoledronate; IBA, ibandronate; RIS, risedronate
Table 2 Multivariable Cox regression of factors potentially associated
with TTO of ONJ in patients with cancer taking ZOL (Model 1) and in
non-cancer patients taking ALE (Model 2). Cluster conﬁdence intervals
were calculated using the study country as cluster
Model 1 Model 2
Patients with
cancer taking ZOL
Non-cancer patients
taking ALE
Male sex (1 = yes; 0 = no) 1.25 [0.92, 1.68] 1.12 [0.50, 2.53]
Age/10 (years) 0.97 [0.92, 1.03] 1.06 [0.83, 1.34]
Dentoalveolar surgery
(1 = yes; 0 = no)
0.71 ** [0.92, 1.03] 1.03 [0.68, 1.23]
Type 2 Diabetes
Mellitus (1 = yes; 0 =no)
1.00 [0.92, 1.09] 0.94 [0.59, 1.51]
Smoking (1 = yes; 0 = no) 1.00 [0.74, 1.36] 1.05 [0.70, 1.58]
Corticosteroids
(1 = yes; 0 = no)
1.18 [0.92, 1.50] 1.06 [0.90, 1.25]
Antiangiogenics
(1 = yes; 0 = no)
1.10 * [1.01, 1.19] –
N 212 84
Values of hazard rates from multivariable Cox regression with 95% con-
ﬁdence intervals in brackets.
*P < 0.05, **P < 0.01.
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6.2 years for PAM. With respect to the cumulative inci-
dence (numbers and percentages) of individuals being
diagnosed with ONJ at different time points after com-
mencement of BP therapy (Figure 1), our analysis shows
that it took 4.1 years for 75% of ZOL-exposed patients
with ONJ and 8.5 years for 75% of ALE-exposed patients
with ONJ to develop their disease. Also, 50% of ZOL-
exposed and ALE-exposed ONJ individuals developed
their disease in 2.2 and 6 years.
Our results are not notably different from those of pre-
vious studies, which were mostly single centre and had
much smaller cohorts. The three largest single-centre
studies performed so far include the 60 ZOL ONJ cases
reported by Watters et al (Marx et al, 2007; Watters
et al, 2013), the 27 ALE ONJ cases described by Marx
et al (Marx et al, 2007; Watters et al, 2013) and the 31
ZOL- and 16 ALE-related ONJ cases reported by Lazaro-
vici et al (Lazarovici et al, 2009), which grouped
together make up a smaller sample than the one we
recruited and studied. These studies reported a median
time to onset of 1.75 years for ZOL-related ONJ (Marx
et al, 2007; Watters et al, 2013), 5.7 years for ALE-
related ONJ (Marx et al, 2007; Watters et al, 2013) and
median times of 2 and 5 years the ZOL-related and
ALE-related ONJ, respectively (Lazarovici et al, 2009).
Our study conﬁrms that ZOL is associated with a shorter
TTO with respect to ALE (Bamias et al, 2005; Mavro-
kokki et al, 2007; Pozzi et al, 2007; Boonyapakorn et al,
2008; Vahtsevanos et al, 2009; Thumbigere-Math et al,
2012; Watters et al, 2013), which is consistent with the
greater potency and better bioavailability of intravenous
ZOL. However, in the present study, the median TTO
was slightly longer than in previous studies for both
ZOL and ALE.
Another strength of this study is the use of multivari-
able analysis to investigate the joint association of poten-
tial risk factors with TTO. Previous studies suggested that
a number of risk factors may have an ‘additive’ impact on
ONJ pathogenesis, therefore leading to shorter TTO
(Bamias et al, 2005; Mavrokokki et al, 2007; Pozzi et al,
2007; Boonyapakorn et al, 2008; Palaska et al, 2009;
Vahtsevanos et al, 2009; Saia et al, 2010; Hasegawa et al,
2012; Thumbigere-Math et al, 2012; Fleisher et al, 2013;
Watters et al, 2013). These factors included corticosteroid
use, smoking, alcohol, T2DM, dental extraction and use
of dentures (Bamias et al, 2005; Mavrokokki et al, 2007;
Pozzi et al, 2007; Boonyapakorn et al, 2008; Palaska
et al, 2009; Vahtsevanos et al, 2009; Saia et al, 2010;
Hasegawa et al, 2012; Watters et al, 2013). Our study
considered up to seven risk factors in a multivariable
regression model (Harrell et al, 1996) and shows that
none of the previously suggested variables is associated
with shorter TTO, including dental risk factors (alveolar
surgery and use of dentures). In the subgroup of patients
with cancer taking ZOL, the only factor associated with
shorter TTO in the present study was the use of antiangio-
genic agents (Table 2). This was not unexpected, as
antiangiogenic medications are known to cause ONJ per
se. Quite surprisingly, a history of dentoalveolar surgery
to the jawbones was associated with a lower hazard for
ONJ in the same subgroup of patients with cancer taking
ZOL. It is not clear why ONJ developed faster in individ-
uals who had not received dentoalveolar surgery. Of note,
despite the relatively large number of subjects compared
to the predictors (seven for Model 1 and six for Model 2),
the estimated hazard ratios have wide 95% CI, suggesting
that larger samples are needed to estimate these effects
more precisely.
A limitation of the present study lies in its retrospective
nature. However, provided that the outcome can be thor-
oughly assessed, retrospective cohort designs offer a num-
ber of advantages over prospective cohort designs if the
time to outcome is long (Hudson et al, 2005). For exam-
ple, based on the present study, one can estimate that a
hypothetical prospective study observing patients with
cancer for 2 years after the start of ZOL therapy would
identify less than 50% of incident ONJ cases. This would
not only decrease the conﬁdence with such incidence esti-
mate can be accepted, but also may identify different risk
factors from those identiﬁable with a longer follow-up.
Conclusions
This is the largest study performed to date to investigate
TTO and its risk factors. It has been conducted in a large
well-phenotyped multicentre cohort, with a strict deﬁnition
of the outcomes, clear diagnostic criteria and the use of
multivariable regression modelling. We believe that its
ﬁndings can be promptly translated into clinical applica-
tion to inform the design of clinical trials, epidemiological
studies and surveillance programmes. For example, a fol-
low-up of at least 2.2 and 6.0 years is needed to capture
at least 50% of the incident cases of ONJ in ZOL and
ALE users, respectively. Corresponding ﬁgures of 4.1 and
8.5 years are needed to capture instead 75% of ZOL-
exposed and ALE-exposed ONJ incident cases. Clinicians
should expect that ZOL-treated patients with cancer who
also receive antiangiogenic therapy may develop ONJ ear-
lier than other patients.
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University Hospital, Denmark); Gennaro Sadile, Stefania
Leuci (Federico II University, Italy); Cristina Mirelli, Giu-
lio Conti, Rita Maiavacca (Fondazione IRCCS Ca Granda,
Ospedale Maggiore Policlinico, Italy); Masahiro Urade,
Hiromitsu Kishimoto, Shin Okui, Yusuke Zushi, Michiyo
Yamamura, Kyohei Yoshikawa (Hyogo College of Medi-
cine, Japan); Giovanna Mansueto (IRCCS, Referral Cancer
Center of Basilicata, Italy); Patrik KE Magnusson
(Karolinska Institutet, Sweden); Shina Popat (King’s Col-
lege Hospital, UK); Barbara Kirnbauer, Barbara Ober-
mayer-Pietsch, Norbert Jakse (Medical University Graz,
Austria); Umberto Mariani, Valeria Martini (Ospedale
Papa Giovanni XXIII, Italy); Antonella Fasciolo, Iolanda
De Martino, Manuela Alessio (Ospedale SS Antonio e
Biagio e C Arrigo, Italy); Jacinto F Sanroman (Policlinico
Vigo SA, Spain); Sara Grammatico (Sapienza University,
Italy); Giovanni Siniscalchi, Angelo Itro (Second Univer-
sity of Naples, Italy); Bernadett Balla, Janos P. Kosa,
Mihaly Vaszilko (Semmelweis University Medical School,
Hungary); John Lo (The University of Hong Kong, Hong
Kong); Eleni Besi, Francesco D’Aiuto, Kwee Yong, Nikos
Donos, Valeria Mercadante (University College London,
UK); Robert Stein, Shirley D’Sa (University College Lon-
don Hospital, UK); Elena Varoni (Universita degli Studi
di Milano, Italy); Damiano Soma, Silvio Meloni (Univer-
sity Hospital of Sassari, Italy); Jane Evely, Anita Hanson
(University of Liverpool, UK); Francesco Giancola, Olga
Di Fede, Vera Panzarella (University of Palermo, Italy);
Giordana Bettini (University of Padua, Italy); Elisabetta
Merigo, Giovanni Mergoni, Paolo Vescovi (University of
Parma, Italy); Sergio Gandolfo, Roberto Marino, Mattia
Berrone (University of Turin, Italy); Alessio Gambino,
Elisa Menegatti, Roberto Broccoletti (University of Turin,
CIR Dental School, Italy); Elena Hens, Leticia Bagan
(University of Valencia, Spain).
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